Search

Your search keyword '"Zhang Liangqing"' showing total 374 results
Start Over Author "Zhang Liangqing"
374 results on '"Zhang Liangqing"'

2. Availability and affordability of blood pressure-lowering medicines and the effect on blood pressure control in high-income, middle-income, and low-income countries: an analysis of the PURE study data

Author

Marjan W Attaei, MA, Rasha Khatib, PhD, Prof Martin McKee, DSc, Prof Scott Lear, PhD, Prof Gilles Dagenais, MD, Ehimario U Igumbor, PhD, Khalid F AlHabib, MD, Prof Manmeet Kaur, PhD, Lanthe Kruger, PhD, Prof Koon Teo, PhD, Fernando Lanas, MD, Khalid Yusoff, MD, Aytekin Oguz, MD, Prof Rajeev Gupta, PhD, Afzalhussein M Yusufali, MD, Ahmad Bahonar, MD, Prof Raman Kutty, MD, Prof Annika Rosengren, MD, Prof Viswanathan Mohan, DSc, Prof Alvaro Avezum, PhD, Prof Rita Yusuf, PhD, Prof Andrzej Szuba, PhD, Sumathy Rangarajan, MSc, Clara Chow, PhD, Prof Salim Yusuf, DPhil, S Yusuf, S Rangarajan, K K Teo, C K Chow, M O'Donnell, A Mente, D Leong, A Smyth, P Joseph, S Islam, M Zhang, W Hu, C Ramasundarahettige, G Wong, L Dayal, A Casanova, M Dehghan, G Lewis, A Aliberti, A Reyes, A Zaki, B Lewis, B Zhang, D Agapay, D Hari, E Milazzo, E Ramezani, F Hussain, F Shifaly, I Kay, J Rimac, J Swallow, L Heldman, M(a) Mushtaha, M(o) Mushtaha, M Trottier, N Aoucheva, N Kandy, P Mackie, R Solano, S Chin, S Ramacham, S Shahrook, S Trottier, T Tongana, W ElSheikh, J Lindeman, M McQueen, K Hall, J Keys, X Wang, J Keneth, A Devanath, R Diaz, A Orlandini, B Linetsky, S Toscanelli, G Casaccia, JM Maini Cuneo, O Rahman, R Yusuf, AK Azad, KA Rabbani, HM Cherry, A Mannan, I Hassan, AT Talukdar, RB Tooheen, MU Khan, M Sintaha, T Choudhury, R Haque, S Parvin, A Avezum, GB Oliveira, CS Marcilio, AC Mattos, K Teo, J Dejesus, W Elsheikh, G Dagenais, P Poirier, G Turbide, D Auger, A LeBlanc De Bluts, MC Proulx, M Cayer, N Bonneville, S Lear, D Gasevic, E Corber, V de Jong, I Vukmirovich, A Wielgosz, G Fodor, A Pipe, A Shane, F Lanas, P Seron, S Martinez, A Valdebenito, M Oliveros, Li Wei, Liu Lisheng, Chen Chunming, Wang Xingyu, Zhao Wenhua, Zhang Hongye, JiaXuan, Hu Bo, Sun Yi, Bo Jian, Zhao Xiuwen, Chang Xiaohong, Chen Tao, Chen Hui, Deng Qing, Cheng Xiaoru, He Xinye, Li Jian, Li Juan, Liu Xu, Ren Bing, Wang Wei, Wang Yang, Yang Jun, Zhai Yi, Zhu Manlu, Lu Fanghong, Wu Jianfang, Li Yindong, Hou Yan, Zhang Liangqing, Guo Baoxia, Liao Xiaoyang, Zhang Shiying, BianRongwen, TianXiuzhen, Li Dong, Chen Di, Wu Jianguo, Xiao Yize, Liu Tianlu, Zhang Peng, Dong Changlin, Li Ning, Ma Xiaolan, Yang Yuqing, Lei Rensheng, Fu Minfan, He Jing, Liu Yu, Xing Xiaojie, Zhou Qiang, P Lopez-Jaramillo, PA Camacho Lopez, R Garcia, LJA Jurado, D Gómez-Arbeláez, JF Arguello, R Dueñas, S Silva, LP Pradilla, F Ramirez, DI Molina, C Cure-Cure, M Perez, E Hernandez, E Arcos, S Fernandez, C Narvaez, J Paez, A Sotomayor, H Garcia, G Sanchez, T David, A Rico, P Mony, M Vaz, A V Bharathi, S Swaminathan, K Shankar, AV Kurpad, KG Jayachitra, N Kumar, HAL Hospital, V Mohan, M Deepa, K Parthiban, M Anitha, S Hemavathy, T Rahulashankiruthiyayan, D Anitha, K Sridevi, R Gupta, RB Panwar, I Mohan, P Rastogi, S Rastogi, R Bhargava, R Kumar, J S Thakur, B Patro, PVM Lakshmi, R Mahajan, P Chaudary, V Raman Kutty, K Vijayakumar, K Ajayan, G Rajasree, AR Renjini, A Deepu, B Sandhya, S Asha, HS Soumya, R Kelishadi, A Bahonar, N Mohammadifard, H Heidari, K Yusoff, TST Ismail, KK Ng, A Devi, NM Nasir, MM Yasin, M Miskan, EA Rahman, MKM Arsad, F Ariffin, SA Razak, FA Majid, NA Bakar, MY Yacob, N Zainon, R Salleh, MKA Ramli, NA Halim, SR Norlizan, NM Ghazali, MN Arshad, R Razali, S Ali, HR Othman, CWJCW Hafar, A Pit, N Danuri, F Basir, SNA Zahari, H Abdullah, MA Arippin, NA Zakaria, I Noorhassim, MJ Hasni, MT Azmi, MI Zaleha, KY Hazdi, AR Rizam, W Sazman, A Azman, R Khatib, U Khammash, A Khatib, R Giacaman, R Iqbal, A Afridi, R Khawaja, A Raza, K Kazmi, A Dans, HU Co, JT Sanchez, L Pudol, C Zamora-Pudol, LAM Palileo-Villanueva, MR Aquino, C Abaquin, SL Pudol, ML Cabral, W Zatonski, A Szuba, K Zatonska, R Ilow#, M Ferus, B Regulska-Ilow, D Różańska, M Wolyniec, KF AlHabib, A Hersi, T Kashour, H Alfaleh, M Alshamiri, HB Altaradi, O Alnobani, A Bafart, N Alkamel, M Ali, M Abdulrahman, R Nouri, A Kruger, H H Voster, A E Schutte, E Wentzel-Viljoen, FC Eloff, H de Ridder, H Moss, J Potgieter, AA Roux, M Watson, G de Wet, A Olckers, JC Jerling, M Pieters, T Hoekstra, T Puoane, E Igumbor, L Tsolekile, D Sanders, P Naidoo, N Steyn, N Peer, B Mayosi, B Rayner, V Lambert, N Levitt, T Kolbe-Alexander, L Ntyintyane, G Hughes, R Swart, J Fourie, M Muzigaba, S Xapa, N Gobile, K Ndayi, B Jwili, K Ndibaza, B Egbujie, A Rosengren, K Bengtsson Boström, U Lindblad, P Langkilde, A Gustavsson, M Andreasson, M Snällman, L Wirdemann, K Pettersson, E Moberg, K Yeates, J Sleeth, K Kilonzo, A Oguz, AAK Akalin, KBT Calik, N Imeryuz, A Temizhan, E Alphan, E Gunes, H Sur, K Karsidag, S Gulec, Y Altuntas, AM Yusufali, W Almahmeed, H Swidan, EA Darwish, ARA Hashemi, N Al-Khaja, JM Muscat-Baron, SH Ahmed, TM Mamdouh, WM Darwish, MHS Abdelmotagali, SA Omer Awed, GA Movahedi, H Al Shaibani, RIM Gharabou, DF Youssef, AZS Nawati, ZAR Abu Salah, RFE Abdalla, SM Al Shuwaihi, MA Al Omairi, OD Cadigal, R.S. Alejandrino, J Chifamba, L Gwaunza, G Terera, C Mahachi, P Murambiwa, T Machiweni, and R Mapanga

Subjects
Public aspects of medicine, RA1-1270
Abstract

Background: Hypertension is considered the most important risk factor for cardiovascular diseases, but its control is poor worldwide. We aimed to assess the availability and affordability of blood pressure-lowering medicines, and the association with use of these medicines and blood pressure control in countries at varying levels of economic development. Methods: We analysed the availability, costs, and affordability of blood pressure-lowering medicines with data recorded from 626 communities in 20 countries participating in the Prospective Urban Rural Epidemiological (PURE) study. Medicines were considered available if they were present in the local pharmacy when surveyed, and affordable if their combined cost was less than 20% of the households' capacity to pay. We related information about availability and affordability to use of these medicines and blood pressure control with multilevel mixed-effects logistic regression models, and compared results for high-income, upper-middle-income, lower-middle-income, and low-income countries. Data for India are presented separately because it has a large generic pharmaceutical industry and a higher availability of medicines than other countries at the same economic level. Findings: The availability of two or more classes of blood pressure-lowering drugs was lower in low-income and middle-income countries (except for India) than in high-income countries. The proportion of communities with four drug classes available was 94% in high-income countries (108 of 115 communities), 76% in India (68 of 90), 71% in upper-middle-income countries (90 of 126), 47% in lower-middle-income countries (107 of 227), and 13% in low-income countries (nine of 68). The proportion of households unable to afford two blood pressure-lowering medicines was 31% in low-income countries (1069 of 3479 households), 9% in middle-income countries (5602 of 65 471), and less than 1% in high-income countries (44 of 10 880). Participants with known hypertension in communities that had all four drug classes available were more likely to use at least one blood pressure-lowering medicine (adjusted odds ratio [OR] 2·23, 95% CI 1·59–3·12); p

Published
2017
Full Text
View/download PDF

14. Course of illness and outcomes in older COVID-19 patients treated with HFNC: a retrospective analysis

Author

Deng, Liehua, Lei, Shaoqing, Wang, Xiaoyan, Jiang, Fang, Lubarsky, David A, Zhang, Liangqing, Liu, Danyong, Han, Conghua, Zhou, Dunrong, Wang, Zheng, Sun, Xiaocong, Zhang, Yuanli, Cheung, Chi Wai, Wang, Sheng, Xia, Zhongyuan, Applegate, Richard L, Tang, Jing, Mai, Zhenhua, Liu, Hong, and Xia, Zhengyuan

Subjects
Clinical Research, Lung, Infectious Diseases, Aging, Good Health and Well Being, Aged, COVID-19, Cannula, China, Female, Hospital Mortality, Humans, Intensive Care Units, Length of Stay, Logistic Models, Male, Multivariate Analysis, Oxygen Inhalation Therapy, Respiratory Distress Syndrome, Retrospective Studies, high-flow nasal cannula therapy, acute respiratory distress syndrome, elderly patients, Biochemistry and Cell Biology, Physiology, Oncology and Carcinogenesis, Developmental Biology
Abstract

Coronavirus disease-2019 (COVID-19) has rapidly spread worldwide and causes high mortality of elderly patients. High-flow nasal cannula therapy (HFNC) is an oxygen delivery method for severely ill patients. We retrospectively analyzed the course of illness and outcomes in 110 elderly COVID-19 patients (≥65 years) treated with HFNC from 6 hospitals. 38 patients received HFNC (200 mmHg < PaO2/FiO2 ≤ 300 mmHg, early HFNC group), and 72 patients received HFNC (100 mmHg < PaO2/FiO2 ≤ 200 mmHg, late HFNC group). There were no significant differences of sequential organ failure assessment (SOFA) scores and APECH II scores between early and late HFNC group on admission. Compared with the late HFNC group, patients in the early HFNC group had a lower likelihood of developing severe acute respiratory distress syndrome (ARDS), longer time from illness onset to severe ARDS and shorter duration of viral shedding after illness onset, as well as shorter lengths of ICU and hospital stay. 24 patients died during hospitalization, of whom 22 deaths (30.6%) were in the late HFNC group and 2 (5.3%) in the early HFNC group. The present study suggested that the outcomes were better in severely ill elderly patients with COVID-19 receiving early compared to late HFNC.

Published
2021

17. The Outcome Impact of Early vs Late HFNC Oxygen Therapy in Elderly Patients with COVID-19 and ARDS

Author

Deng, Liehua, Lei, Shaoqing, Jiang, Fang, Lubarsky, David A, Zhang, Liangqing, Liu, Danyong, Han, Conghua, Zhou, Dunrong, Wang, Zheng, Sun, Xiaocong, Zhang, Yuanli, Cheung, Chi Wai, Wang, Sheng, Xia, Zhong-yuan, Applegate, Richard L, Liu, Hong, Tang, Jing, and Xia, Zhengyuan

Subjects
Aging, Clinical Research, Infectious Diseases, Good Health and Well Being
Abstract

AbstractCoronavirus disease-2019 (COVID-19) has rapidly spread worldwide. High-flow nasal cannula therapy (HFNC) is a major oxygen supporting therapy for severely ill patients, but information regarding the timing of HFNC application is scarce, especially in elderly patients. We retrospectively analyzed the clinical data of 110 elderly patients (≥65 years) who received HFNC from Renmin Hospital of Wuhan University, People’s Hospital of Xiantao City and Chinese Medicine Hospital of Shishou City in Hubei Province, China, and from Affiliated Hospital of Guangdong Medical University, People’s Hospital of Yangjiang City, People’s Hospital of Maoming City in Guangdong Province, China.Of the 110 patients, the median age was 71 years (IQR, 68-78) and 59.1% was male. Thirty-eight patients received HFNC when 200 mmHg < PO2/FiO2 ≤ 300 mmHg (early HFNC group), and 72 patients received HFNC treatment when 100 mmHg < PaO2/FiO2 ≤ 200 mmHg (late HFNC group). Compared with the late HFNC group, patients in the early HFNC group had a lower likelihood of developing severe ARDS, longer time from illness onset to severe ARDS and shorter duration of viral shedding after illness onset, as well as shorter lengths of ICU and hospital stay. Twenty-four patients died during hospitalization, of whom 22 deaths (30.6%) were in the late HFNC group and 2(5.3%) in the early HFNC group. It is concluded that the Prognosis was better in severely ill elderly patients with COVID-19 receiving early compared to late HFNC. This suggests HFNC could be considered early in this disease process.

Published
2020

30. Propofol and salvianolic acid A synergistically attenuated cardiac ischemia–reperfusion injury in diabetic mice via modulating the CD36/AMPK pathway

Author

Zhou, Jiaqi, primary, Xia, Weiyi, additional, Chen, Jiajia, additional, Han, Kaijia, additional, Jiang, Yuxin, additional, Zhang, Anyuan, additional, Zhou, Dongcheng, additional, Liu, Danyong, additional, Lin, Jiefu, additional, Cai, Yin, additional, Chen, Guanghua, additional, Zhang, Liangqing, additional, Xu, Aimin, additional, Xu, Youhua, additional, Han, Ronghui, additional, and Xia, Zhengyuan, additional

Published
2024
Full Text
View/download PDF

38. Addressing the consensus on information sharing in CPFR information systems: Insights from manufacturer – retailer dyads.

Author

Zhang, Liangqing, Liu, Hefu, and Cai, Zhao

Subjects
INFORMATION sharing, INFORMATION storage & retrieval systems, MANUFACTURING industries, DYADS
Abstract

This study investigated the mechanism of improving consensus between one dominant manufacturer and retailers in evaluating retailers' information sharing in a Collaborative Planning, Forecasting, and Replenishment (CPFR) system. IT capability, goodwill trust, and competence trust were proposed as antecedents of this consensus based on organizational information processing theory (OIPT). A matched questionnaire survey was conducted, generating 253 manufacturer-retailer dyads for analysis. Consensus on information sharing was operationalized by the degree-symmetric model (DSM). The empirical results showed that retailers' IT capability, goodwill trust, and competence trust in the dominant manufacturer were positively related to the consensus on information sharing. Furthermore, the interaction between retailers' IT capability and goodwill trust was negatively related to this consensus, whereas the interaction effect of retailers' IT capability and competence trust was positive. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

42. Propofol and salvianolic acid A synergistically attenuated hypoxia/reoxygenation induced H92 cells injury under high-glucose and high-fat condition via modulating CD36

Author

Zhou, Jiaqi, primary, Han, Ronghui, additional, Zhang, Anyuan, additional, Chen, Jiajia, additional, Jiang, Yuxin, additional, Zhou, Dongcheng, additional, Liu, Danyong, additional, Zhang, Liangqing, additional, Xia, Weiyi, additional, Xu, Youhua, additional, and Xia, Zhengyuan, additional

Published
2023
Full Text
View/download PDF

43. Propofol and salvianolic acid A synergistically ameliorates LPS-induced H92 cells injury under hyperglycemia via enhancing SIRT1 to inhibit NLRP3 dependent-pyroptosis

Author

Zhang, Anyuan, primary, Han, Ronghui, additional, Zhou, Jiaqi, additional, Han, Kaijia, additional, Chen, Jiajia, additional, Yang, Yuhui, additional, Zhang, Xihe, additional, Shangguan, Wangning, additional, Zhang, Liangqing, additional, Tang, Jing, additional, and Xia, Zhengyuan, additional

Published
2023
Full Text
View/download PDF

44. Downregulation in Connexin43 expression is associated with reduced ferroptosis and enhanced tolerance to myocardial ischemia-reperfusion injury in type 1 diabetic mice

Author

Chen, Jiajia, primary, Liu, Danyong, additional, Zhou, Jiaqi, additional, Zhou, Dongcheng, additional, Zhang, Anyuan, additional, Jiang, Yuxing, additional, Lin, Jiefu, additional, Zhang, Liangqing, additional, Han, Ronghui, additional, Yang, Yuhui, additional, and Xia, Zhengyuan, additional

Published
2023
Full Text
View/download PDF

46. Propofol inhibits myocardial injury induced by microvesicles derived from hypoxiareoxygenated endothelial cells via lncCCT4-2/CCT4 signaling

Author

Zhang,Xiaojun, Wang,Changsen, Xu,Hao, Cai,Shuyun, Liu,Keyu, Li,Simeng, Chen,Linming, Shen,Siman, Gu,Xiaoxia, Tang,Jing, Xia,Zhengyuan, Hu,Zhe, Ma,Xiaotang, Zhang,Liangqing, Zhang,Xiaojun, Wang,Changsen, Xu,Hao, Cai,Shuyun, Liu,Keyu, Li,Simeng, Chen,Linming, Shen,Siman, Gu,Xiaoxia, Tang,Jing, Xia,Zhengyuan, Hu,Zhe, Ma,Xiaotang, and Zhang,Liangqing

Abstract

Background Ischemia-reperfusion (IR) induces increased release of extracellular vesicles in the heart and exacerbates myocardial IR injury. We have previously shown that propofol attenuates hypoxia/reoxygenation (HR)-induced injury in human umbilical vein endothelial cells (HUVECs) and that microvesicles derived from propofol-treated HUVECs inhibit oxidative stress in endothelial cells. However, the role of microvesicles derived from propofol post-treated HUVECs ((HR + P)-EMVs) in IR-injured cardiomyocytes is unclear. In this study, we aimed to investigate the role of (HR + P)-EMVs in cardiac IR injury compared to microvesicles derived from hypoxic/reoxygenated HUVECs (HR-EMVs) and to elucidate the underlying mechanisms. Methods Hypoxia/reoxygenation (HR) models of HUVECs and AC16 cells and a mouse cardiac IR model were established. Microvesicles from HR-injured HUVECs, DMSO post-treated HUVECs and propofol post-treated HUVECs were extracted by ultra-high speed centrifugation, respectively. The above EMVs were co-cultured with HR-injured AC16 cells or injected intracardially into IR mice. Flow cytometry and immunofluorescence were used to determine the levels of oxidative stress and apoptosis in cardiomyocytes. Apoptosis related proteins were detected by Western blot. Echocardiography for cardiac function and Evans blue-TTC staining for myocardial infarct size. Expression of lncCCT4-2 in EMVs and AC16 cells was analysed by whole transcriptome sequencing of EMVs and RT-qPCR. The molecular mechanism of inhibition of myocardial injury by (HR + P)-EMVs was elucidated by lentiviral knockdown of lncCCT4-2, plasmid overexpression or knockdown of CCT4, and actinomycin D assay. Results In vitro and in vivo experiments confirmed that HR-EMVs exacerbated oxidative stress and apoptosis in IR-injured cardiomyocytes, leading to increased infarct size and worsened cardiac function. Notably, (HR + P)-EMVs induced significantly less oxidative stress and apoptosis in IR-inju

Published
2023

50. Additional file 1 of Propofol inhibits myocardial injury induced by microvesicles derived from hypoxia-reoxygenated endothelial cells via lncCCT4-2/CCT4 signaling

Author

Zhang, Xiaojun, Wang, Changsen, Xu, Hao, Cai, Shuyun, Liu, Keyu, Li, Simeng, Chen, Linming, Shen, Siman, Gu, Xiaoxia, Tang, Jing, Xia, Zhengyuan, Hu, Zhe, Ma, Xiaotang, and Zhang, Liangqing

Abstract

Additional file 1: Supplementary Figure 1 Normoxic AC16 cells were co-cultured with HR-EMVs at different concentrations (10^7, 10^8 and 10^9 particles/ml) for 24 h: (A) CCK-8 assay for AC16 cell viability. (B) Flow cytometry detection of apoptotic rate in AC16 cells after annexin V-FITC/PI double staining. (C) quantitative analysis of apoptotic cells. HR-injured AC16 cells were co-cultured with HR-EMVs, (HR + P25)-EMVs, (HR + P50)-EMVs, (HR + P100)-EMVs, and (HR + P150)-EMVs for 24 h, respectively: (D) CCK-8 assay for AC16 cell viability. (E) Flow cytometry detection of apoptotic rate in AC16 cells after annexin V-FITC/PI double staining. (F) quantitative analysis of apoptotic cells. These data were representative results (n = 3) of three repetitions. *P < 0.05, **P < 0.01, ***P < 0.001, ns, not significant. Data are expressed as mean ± SEM. Supplementary Figure 2 (A) HUVECs were infected with LV-sh-lncCCT4 or LV-sh-NC for 72 h. The knockdown efficiency of lncCCT4-2 in HUVECs was detected by RT-qPCR. Transfection of AC16 cells with sh-CCT4 and OE-CCT4 plasmids for 48 h: (B-C) Detection of CCT4 mRNA expression in AC16 cells by RT-qPCR. (D-E) Western blotting analysis of CCT4 protein expression in AC16 cells to detect the transfection efficiency of sh-CCT4 and OE-CCT4 plasmids. These data were representative results (n = 3) of three repetitions. *P < 0.05, **P < 0.01, ***P < 0.001, ns, not significant. Data are expressed as mean ± SEM. Supplementary 3 The genomic location and sequence of lncCCT4-2 and CCT4. Supplementary 4 Prediction of lncCCT4-2 and CCT4 mRNA binding sites.

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results